Research Article

The Role of T Cells and Macrophages in Asthma Pathogenesis: A New Perspective on Mutual Crosstalk

Xueyi Zhu,1 Jie Cui,1 La Yi,1 Jingjing Qin,1 Wuniqiemu Tulake,1 Fangzhou Teng,1 Weifeng Tang,1 Ying Wei,1,2 and Jingcheng Dong1,2

1Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
2Institutes of Integrative Medicine, Fudan University, Shanghai 200040, China

Correspondence should be addressed to Ying Wei; weiying_acup@126.com and Jingcheng Dong; jcdong2004@126.com

Received 28 June 2020; Revised 9 August 2020; Accepted 10 August 2020; Published 19 August 2020

Academic Editor: Tânia Silvia Fröde

Copyright © 2020 Xueyi Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Asthma is a common chronic airway disease characterized by airway inflammation, hyperresponsiveness, and variable airway obstruction, which is often attributed to gene-environment interactions [1, 2]. There are approximately 334 million people worldwide suffering from asthma [3]. Multiple immune cells are involved with the development of asthma, such as T cells, macrophages, dendritic cells, eosinophils, neutrophils, mast cells, and basophils [4]. Eosinophilic asthma, neutrophilic asthma, and mixed granulocytic asthma are all influenced by cytokines and chemokines from these immune cells [5]. Recent studies have highlighted that the imbalance of T cells or macrophage dysfunction contributes to the progression of asthma [6]. However, uncertainty remains as to the crosstalk of these two cells. To shed light on this perspective, we summarize the role of both T cells and macrophages as well as their interactions in asthma pathogenesis, hoping to provide a basis for potential targets in the future treatment of asthma. We also speculate that extracellular vesicles might be the main mediator of their crosstalk. Alternatively, the corresponding cytokine storm is probably involved with severe asthma.

1. Introduction

Asthma is a common chronic airway disease characterized by airway inflammation, hyperresponsiveness, and variable airway obstruction, which is often attributed to gene-environment interactions [1, 2]. There are approximately 334 million people worldwide suffering from asthma [3]. Multiple immune cells are involved with the development of asthma, such as T cells, macrophages, dendritic cells, eosinophils, neutrophils, mast cells, and basophils [4]. Eosinophilic asthma, neutrophilic asthma, and mixed granulocytic asthma are all influenced by cytokines and chemokines from these immune cells [5]. Recent studies have highlighted that the imbalance of T cells or macrophage dysfunction contributes to the progression of asthma [6]. However, uncertainty remains as to the crosstalk of these two cells. To shed light on this perspective, we summarize the role of both T cells and macrophages as well as their interactions in asthma pathogenesis, hoping to provide a basis for potential targets in the future treatment of asthma. We also speculate that extracellular vesicles might be the main mediator of their crosstalk. Alternatively, the corresponding cytokine storm is probably involved with severe asthma.

2. Imbalance of T Cells in Asthma Pathogenesis

T cells, derived from lymphoid stem cells in the bone marrow, participate in antigen-specific responses. When naïve T (Tn) cells encounter the antigen, they have the potential to differentiate into effector T cells and a small portion of memory T cells. Effector T cells include T helper (Th) 1, Th2, Th17, Th22, Th9, Th25, T regulatory (Treg), T follicular helper, natural killer T cells, and cytotoxic CD8+ T lymphocytes [7]. They not only regulate innate immune cells (macrophages, eosinophils, mast cells, basophils, etc.) but also stimulate B cells to resist viruses. T cells also generate enormous cytokines and chemokines to amplify the immune response [8, 9], thus enhancing airway smooth muscle contraction, mucus secretion, and airway hyperresponsiveness (AHR), as well as T cell proliferation in asthma [10]. Here, we review the detailed role of these cells in asthma (Figure 1).

2.1. Th Cells and Treg Cells

2.1.1. Th1/Th2 Imbalance in Eosinophilic Asthma. Th1/Th2 imbalance plays a significant role in asthma pathogenesis. Interleukin- (IL-12 and interferon- (IFN- ) y induce T-bet to stimulate Th1 cells through the signal transducer and
activator of transcription (STAT) 4 signal while IL-4 induces Gata3 to activate Th2 cells via the STAT6 signal [11]. Th1 cells generate IL-2, IFN-γ, and lymphotoxin- (LT-) α, promoting type 1 immunity. They have dual regulatory roles in asthma: they repress Th2 cell activation to confine eosinophilic inflammation but advance neutrophilic inflammation [12]. Raundhal et al. [13] revealed that IFN-γ+Th1 cells were dominant in severe asthma, potentially associated with corticosteroid unresponsiveness. Th1 cell recruitment to the inflammatory sites can be enhanced by CXC chemokine ligand (CXCL) 10 and its cognate CXC chemokine receptor (CXCR) 3, leading to corticosteroid resistance [14]. Notably, Th2 cells are directly triggered by airway epithelial-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin (TSLP)) [15], subsequently secreting Th2-associated cytokines (IL-4, IL-5, and IL-13) [16, 17]. IL-4 and IL-13 urge B cells to produce IgE, mucus secretion, and AHR [18, 19]. IL-5 maintains the survival and vitality of eosinophils, dominant in eosinophilic inflammation and AHR [20]. Moreover, Th2-associated chemokine receptors (CCR3, CCR4, and CCR8) and ligands (CCL1, CCL5, CCL26, and CX3CL1) assist in eosinophil recruitment and AHR [21, 22]. CCL17 and CCL22 also have the capability to increase Th2 cell proliferation via autocrine loops [23]. Although corticosteroid therapies have a great effect on alleviating Th1/Th2 imbalance in asthma, more attention has currently been paid to a

**Figure 1:** Imbalance of T cells in asthma pathogenesis. In response to allergens, the naïve T (Tn) cells are activated by the macrophages and tend to differentiate into T helper (Th) 1, Th2, Th17, Th22, Th9, Th25, T regulatory (Treg), T follicular helper (Tfh), natural killer T (NKT), mucosal-associated invariant T (MAIT), γδT cells, cytotoxic CD8+T lymphocytes (CTLs), and memory T (Tm) cells. They secrete cytokines to activate and recruit the eosinophils, neutrophils, mast cells, and B cells. The arrows represent the secretions from these cells, affecting the progression of asthma. The transcriptional factors T-bet, Gata3, RAR-related orphan receptor (ROR) γt, Foxp3, and PU.1 are necessary to Th1, Th2, Th17, Treg, Th22, and Th9 cell activation. The signal transducer and activator of transcription (STAT) signals are involved in the process. Besides, caspase 8 and the Fas/FasL pathway are related to cell apoptosis mediated by CTLs.
range of treatments targeting Th2-associated cytokines, such as mepolizumab, reslizumab, and lebrikizumab [24, 25].

2.1.2. Th17/Treg Imbalance in Neutrophilic Asthma. Recent studies have demonstrated that Th17/Treg imbalance also remains vital in asthma pathogenesis. IL-6 and IL-23 induce RAR-related orphan receptor (ROR) γt to activate Th17 cells through the STAT3 signal whereas transforming growth factor-β (TGF-β) expresses Foxp3 to promote Treg cell differentiation [26]. Alcorn et al. [27] discussed that Th17 cells produced IL-17A, IL-17F, and IL-22 via the toll-like receptor (TLR) 4/IFN-β (TRIF) pathway, exerting proinflammatory function in neutrophil recruitment and activation. Interestingly, IL-17 has dual regulatory abilities: it recruits neutrophils to the inflammatory site to protect the lungs but aggravates neutrophilic asthma [28, 29]. Rahman et al. [30] found that IL-17A modulated the rapid phosphorylation of mitogen-activated protein kinase (MAPK), expressing eotaxin-1/CCL11. Moreover, the bond between CCR4 or CCR6 and CCL20 enhances Th17 cell recruitment to the lesion [31]. CD25+CD4+Foxp3+Treg cells, expressing B cell lymphoma (BCL) 6 [49], CD4+CXCR5+Tfh cells secrete IL-4 to drive B cells and the subsequent production of immunoglobulin (IgE) [50]. Also, IL-2, IL-4, and IL-13 secreted by Tfh cells expand type 2 inflammation [51, 52].

2.1.3. Th22 Cells. Th22 cell differentiation, closely associated with Th17 cells, is triggered by IL-6 and TGF-β via STAT3 signaling [38]. Besnard et al. [39] proved that the level of IL-4, IL-5, IL-13, and IL-33; counts of eosinophils and neutrophils; and TGF-β regulates the immune response to avoid overactivation, promote immune tolerance, and maintain balance in the immune microenvironment [32]. Associated chemokine receptors (CCR4, CCR5, CCR7, and CCR8) enhance Treg cell recruitment [33]. There is also a large amount of IL-35-induced Treg cells, called iTreg cells. They serve as immunomodulators to suppress the inflammatory response [34]. The Th17/Treg imbalance mechanism, which leads to neutrophilic, severe, or corticosteroid-resistant asthma, is a supplement to the Th1/Th2 imbalance mechanism in asthma [35, 36]. Of note, novel therapeutics targeting these cytokines have gained more and more attention in corticosteroid-insensitive asthma [37].

2.1.4. Th9 or Th25 Cells. Th2 cells express the transcriptional factors PU.1 and interferon regulatory factor (IRF) 4 in the presence of IL-4 and TGF-β, thus driving Th9 cell activation via the STAT16 signal [42–44]. Reversely, Th9 cells are suppressed by the overexpression of B lymphocyte-induced maturation protein 1 (Blimp-1) [45]. Th9 cells produce IL-9 to recruit and activate mast cells and B cells, associated with IgE elevation and corticosteroid resistance [46, 47]. They also interact with innate lymphoid cell (ILC) 2 to further amplify type 2 inflammation. IL-25 (IL-17E), originated from Th25 cells, also has a close relationship with Th2 cells: it can drive Th2 cell differentiation [48].

2.1.5. T Follicular Helper Cells. IL-6, IL-12, and IL-21 elevate T follicular helper (Tfh) cell differentiation with the combination of inducible T cell costimulator (ICOS) and OX40, expressing B cell lymphoma (BCL) 6 [49]. CD4+CXCR5+Tfh cells secrete IL-4 to drive B cells and the subsequent production of immunoglobulin (IgE) [50]. Also, IL-2, IL-4, and IL-13 secreted by Tfh cells expand type 2 inflammation [51, 52].

2.2. Cytotoxic CD8+ T Lymphocytes. Cytotoxic CD8+ T lymphocytes (CTLs) can be classified into the subtypes similar to the subtypes of Th cells and corresponding functions. As we all know, the CD4/CD8 ratio is considerably higher in asthma; how to maintain it balanced is a key to therapy. CTLs search for and recognize specific antigens presented by major histocompatibility complex (MHC) class I molecules and then combine with T cell receptor (TCR), thus forming complexes. Next, chemicals such as perforin and granzyme are released through direct contact while IgE is correspondingly suppressed. Chávez-Galán et al. [53] pinpointed that CTLs mediated cell apoptosis via caspase 8 and the Fas/FasL pathway, which is also related to the effect of tumor necrosis factor-α (TNF-α). Together with all the influence above, type 1 inflammation is amplified while type 2 inflammation is weakened by CTLs [54].

2.3. Innate-Like T Cells. Innate-like T (ILT) cells, including natural killer T (NKT), mucosal-associated invariant T (MAIT), and γδ T cells, belong to unconventional T cell subgroups [55]. They all have similar functions and express αβ or γδ TCR chains, which can be activated in a TCR-dependent or TCR-independent manner [56]. They generate IL-4, IL-5, IL-13, and IFN-γ to develop Th2 and Th17 cell activations, modulating eosinophilic infiltration and AHR [57]. Meanwhile, IL-17 is secreted to modulate neutrophilic asthma and macrophage proliferation. Lezmi and Leite-de-Moraes [58] confirmed that NKT cells also regulated CTLs and killed infected cells as analogous to CTLs in asthmatic patients.

2.4. Memory T Cells. Memory T (Tm) cells develop immune memory and train the body to react rapidly during the secondary immune response. BCL6, Blimp-1, and histone H3 lysine 4 (H3K4me2) participate in Tm cell differentiation [59, 60]. It was demonstrated that IL-2-resident CD4+ Th2 memory cells promoted eosinophilic asthma and produced IL-5 via IL-33-ST2-p38 kinase signaling [61–63]. Tm cells express IL-17 and CCR7 as well [64]. Furthermore, Tm cell-induced inflammatory response is amplified via IL-25 but suppressed through IL-35 [65].

2.5. Other T Cells (Intraepithelial Lymphocytes and Jurkat T Cells). It was described that CD103+CD69+ intraepithelial lymphocytes (IELs) were remarkably activated in the sputum of asthmatic patients [66]. CD4+CD103+ IELs always remain in the inflammatory tissues. On the other side, Jurkat T cells
3. Macrophage Dysfunction in Asthma Pathogenesis

Macrophages are primarily derived from monocytes in the bone marrow and present in almost all tissues, mainly classified into alveolar macrophages (AMs) and interstitial macrophages (IMs) in the lungs [68]. They not only phagocytose and directly kill antigens to mediate innate immunity but also process and present antigens to assist adaptive immunity in asthma [69]. They produce the oxygen radicals to decrease β-adrenergic response and thromboxane A2 to enhance cholinergic response. It is like a double-edged sword in the inflammation of asthma. Lee et al. [70] demonstrated that the lack of AMs led to the suppression of type 2 inflammation and airway remodeling. However, it was argued that the adoptive immunity of AMs to asthmatic mice attenuated airway hyperreactivity in asthmatic mice. Other mice with removed AMs had worsening lung function and Th2-type inflammatory response exacerbation [71]. It has been generally accepted that macrophage polarization breaks the balance of classically activated (M1)/alternatively activated (M2) macrophages in asthma [72, 73]. IFN-γ, lipopolysaccharide (LPS), and TNF-α stimulate M1 macrophages while IL-4, IL-13, and IL-10 activate M2 macrophages [74]. CCL2 and CXCL4 help develop M2 polarization as well [75] (Figure 2).

3.1. M1 Polarization and Proinflammation in Asthma Pathogenesis

M1 macrophages highly express MHC class II molecules, CD80, CD86, TLR4, and inducible nitric oxide synthase (iNOS), further producing Th1-associated cytokines and airway remodeling. However, it was argued that the adoptive immunity of AMs to asthmatic mice attenuated airway hyperreactivity in asthmatic mice. Other mice with removed AMs had worsening lung function and Th2-type inflammatory response exacerbation [71]. It has been generally accepted that macrophage polarization breaks the balance of classically activated (M1)/alternatively activated (M2) macrophages in asthma [72, 73]. IFN-γ, lipopolysaccharide (LPS), and TNF-α stimulate M1 macrophages while IL-4, IL-13, and IL-10 activate M2 macrophages [74]. CCL2 and CXCL4 help develop M2 polarization as well [75] (Figure 2).

Figure 2: Macrophage dysfunction in asthma pathogenesis. In response to allergens, macrophages differentiate into classically activated (M1) and alternatively activated (M2) macrophages. The arrows refer to the cytokines and chemokines secreted by macrophages, including tumor necrosis factor-α (TNF-α), interleukin (IL), and interferon-γ (IFN-γ). M1 macrophages produce T helper (Th) 1-associated and Th17-associated cytokines, affecting the neutrophils. M2 macrophages further differentiate into M2a, M2b, and M2c macrophages, affecting the eosinophils.
(TNF-α, IL-1β, IL-2, IL-6, and IL-12), Th17-associated cytokines (IL-23 and IL-27), monocyte chemotactic protein (MCP-1), reactive oxygen species (ROS), and chemokines (CXCL9, CXCL10, CXCL11, CXCL16, CCL2, CCL5, and CCL8). M1 macrophages exacerbate the Th1-type and Th17-type inflammatory response, linked with neutrophilic infiltration, corticosteroid resistance, oxidative damage, and AHR [76, 77]. Goleva et al. [78] gave the proof that M1 macrophages had a higher expression in bronchoalveolar lavage fluid (BALF) of corticosteroid-resistant asthmatic patients. Interestingly, the macrophages are characterized by heterogeneity and plasticity that M1 macrophages can differentiate into M2 macrophages.

3.2. M2 Polarization and Its Modulation of Inflammation in Asthma Pathogenesis (a Double-Edged Sword). M2 macrophages have the lower expression of MHC class II molecules and CD86 as well as the higher expression of macrophage mannose receptor (MR), arginase (Arg) 1, CD206, and CD163, modulating eosinophilic infiltration in type 2 inflammation [79]. They are prominent in parasite immunomodulation, tissue remodeling, and Th2 cell differentiation [80]. Melgert et al. [81] observed that M2 macrophages were abundant in the BALF of asthmatic patients. Furthermore, they demonstrated that allergen-induced disease was exacerbated after the adoptive transfer of M2 macrophages [82]. NOD-, LRR-, and pyrin domain-containing (NLRP) 3 inflammasome was proved to have the potential to upregulate IL-4 to promote M2 polarization [83]. Specifically, IL-4 or IL-13 induces M2a macrophages to express IL-10, TGF-β, and chemokines (CCL17, CCL18, CCL22, and CCL24), which participate in Th2-type inflammation, airway remodeling, and parasite immunomodulation. Immune complex (IC) promotes M2b macrophage activation, taking part in Th2-type immune regulation and expressing TNF-α, IL-1β, IL-6, IL-10, and CCL1. IL-10 or prostaglandin (PG) E2 stimulates monocytes to differentiate into M2c macrophages; they further express IL-10, TGF-β, CCL16, CCL18, and CXCL13, repressing inflammation and enhancing tissue repair [84].

3.3. Innate Immune Response Mediated by Macrophages. Macrophages act as the first-line defense in the lungs and the initial responders to immune stimulation, belonging to the innate immune system [85]. Pattern recognition receptors (PRRs) on macrophages, particularly TLRs, recognize pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) on antigens. Then, antigens are endocytosed in macrophages through the interactions and lysosomes are released to kill them. After that, the protein residues are presented on the macrophage surface, forming MHC molecules. It has been pointed out that macrophages regulate the inflammatory microenvironment via autocrine or paracrine [86]. They have the ability to secrete PGE2, PGD2, and D-prostanoid receptor (DP) 1 to enlarge neutrophil migration [87, 88]. Alternatively, macrophage apoptosis, autophagy, and necrosis are closely related to immune response exacerbation or alleviation, probably caused by mitochondrial autophagy or endoplasmic reticulum (ER) stress [89].

4. Crosstalk between T Cells and Macrophages in Asthma Pathogenesis

4.1. Adaptive Immune Response Mediated by T Cells and Macrophages (Cellular Immunity). If the antigens cannot be eliminated in the innate immune response, they will be processed to constitute MHC class I or II molecules and presented on the macrophage surface [90, 91]. Then, the TCR of T cells recognizes and connects them, further joining with costimulatory molecules. A large number of cytokines are gathered to switch on the adaptive immune response. Macrophage migration inhibitory factor (MIF) participates in the modulation of both the innate and adaptive immune responses [92]. Immunological synapse includes B7-1/2 (CD80/CD86) on macrophages, which binds to CD28 and cytokotoxic T lymphocyte-associated protein- (CTLA-) 4 on Tn cells [93]. ICOS matches ICOS-L on Tm cells while OX40 contacts to OX40L [94]. In this process, T cell proliferation is further expanded, and macrophages are also affected (Figure 3).

4.1.1. Macrophages Activate and Suppress T Cell Functions. The antigens on MHC molecules from macrophages ensure CD4+ T cell activation and proliferation in an antigen-specific manner [95]. Bozza et al. [96] proved that macrophages secreted MIF and the lack of MIF reduced activated antigen-specific CD4+ T cells and Th2-associated cytokines, which implied that macrophages might have functions of initiating T cell-mediated immune response. Macrophages also produce prostaglandin and interleukin in an autocrine manner and act on T cells in a paracrine manner [97]. Specifically, macrophages modulate type 1 inflammation. It was confirmed that Th1 cells could be gathered through IFN-γ-dependent CXCR3 ligands from macrophages [98]. AMs secrete IL-12 to amplify type 1 inflammation [99]. Conversely, M2 macrophages function to suppress type 1 inflammation [100]. Turning to Th2 cells, macrophage-derived cytokines (IL-1β and IL-6) and chemokines (CCL1 and CCL22) were identified to promote Th2 cell differentiation from CD4+ T cells and recruit Th2 cells, mediating eosinophilic inflammation with the increase of IL-4 and IL-13 [101]. Lai et al. [102] indicated that IMs expressed TSLP, which was the stimulus of Th2 cell differentiation. IL-18 from macrophages was described to drive type 2 inflammation, Th2 cell differentiation, and AHR [103]. Wills-Karp et al. [104] also observed that IL-33 from macrophages drove Th2-type inflammation, urged by trefoil factor 2 (TFF2) in the house dust mite-induced asthmatic murine model. Additionally, Laidlaw and Boyce [105] proposed that macrophages synthesized and released the leukotriene (LT) C4, which induced Th2 cells and modulated Th2-type inflammation. Takahashi et al. [106] verified that matrix metalloproteinase- (MMP-) 2 had the protective function in allergic asthma, probably through its regulation of M1 macrophage differentiation and further downregulation of Th2-type inflammation. It can be concluded that macrophages can affect both type 1 and type 2 inflammation. Kim et al. [107] confirmed that TNF-α, mainly produced by activated macrophages, alleviated Th1-associated and Th2-associated cytokines, IgE, and airway remodeling. On the other side,
**Figure 3: Crosstalk between T cells and macrophages in asthma pathogenesis.** The arrows represent the cytokines secreted by T cells and macrophages. Macrophages secrete interleukin-10 (IL-10) to repress T helper (Th) 2 and Th17 cells. Similarly, Treg cells secrete IL-10 to inhibit macrophages. Antigen-contained major histocompatibility complex (MHC) class I or II molecules on macrophages bind to the T cell receptor (TCR) on T cells to mediate the adaptive immune response. Extracellular vesicles (EVs) carrying miRNAs (miRNA-142, miRNA-126, miRNA-21, etc.) may be the modulators of the crosstalk between T cells and macrophages. In addition, the imbalance caused by the cytokine storm may be the main cause of severe asthma. The red side refers to the positive feedback loops while the blue side refers to the negative feedback loops.
macrophages are involved in Th17-associated immune response. Song et al. [108] demonstrated that AMs of asthmatic patients increased IL-17, which means there was also an exact relationship between macrophages and Th17 cells, especially in neutrophilic inflammation. Macrophage-associated CCL2, CCL17, and CCL22 promote T cell migration and the progression of inflammation [109]. Besides these promotions of the inflammation, a portion of macrophages has anti-inflammatory functions and modulates the excessive immune response. Kawano et al. [110] illustrated that IL-10 of IMs reduced Th2 and Th17 cells to alleviate neutrophilic asthma via the TLR4/MyD88 pathway. Chakarov et al. [111] also proposed that IMs enhanced T cell proliferation and Treg cell differentiation. In the presence of retinoic acid, AM-associated TGF-β develops Treg cell differentiation [112]. Lu et al. [113] explained that the anti-inflammatory function of IL-27 from M1 macrophages relied on its suppression of Th2-type inflammation via the STAT1 and STAT3 pathways.

4.1.2. T Cells Activate and Suppress Macrophage Functions. Similar to macrophage controlling T cells mentioned above, T cells influence macrophage production, activation, and function. M1 macrophage differentiation is mainly promoted by Th1-associated cytokines (IFN-γ and LPS), and M2 macrophage differentiation is dependent on Th2-associated cytokines (IL-4 and IL-13). Kuchroo et al. [114] proposed that the regulation of macrophage vitality relied on the T cell immunoglobulin and mucin domain-1 (Tim-1) and Tim-3 on T cells. Th cell-secreted granulocyte-monocyte colony-stimulating factor (GM-CSF) initiates macrophage activation and secretion [115]. Th1-derived IFN-γ, IL-2, and TNF-α function together to enhance macrophage endocytosis function, bactericidal capacity, and proliferation [116]. Mukhopadhyay et al. [117] indicated that TNF-α from T cells elevated intercellular cell adhesion molecule-1 (ICAM-1), which ensured that macrophages passed through the blood vessel wall to the inflammatory site. Also, Th2-associated IL-4 motivates macrophage endocytosis ability [118]. Edukulla et al. [119] proved that Th2-associated IL-4 and IL-13 upregulated IL-31 receptor α expression of macrophages, enhancing M2 macrophages. Nobs et al. [120] demonstrated that Th2 cells predominantly expressed the transcription factor pereoxisome proliferator-activated receptor (PPAR) γ, increasing M2 macrophages and AMs, which might be closely associated with IL-33-driven type 2 inflammation. Banerjee and Henderson [121] verified that in the response to the stimulus, the NADPH oxidase catalytic subunit Nox2 (gp91phox) alone or gp91phox and MMP-12 together controlled T cells and regulated Th2-type immunity, then mediating macrophages. It can be seen that gp91phox and MMP-12 may be the targets of restricting the crosstalk between T cells and macrophages. On the aspect of Th17-type immune response, IL-17 stimulates macrophages to amplify antibacterial capability through IL-17RA. IL-17A induces the production of IL-33, and their cooperation increases CXCR2-expressed macrophages, aggravating neutrophilic asthma [122]. Activated NKT cells directly urge macrophage to secrete IL-13 via the contact of invariant TCR-CD1d [123]. They also elevated the IL-33 of AMs via the IL-33/ST2 signaling pathway, mediating AHR [124]. Conversely, macrophage proliferation can be suppressed by IL-10 and TGF-β of Treg cells [125] (Table 1).

4.2. Humoral Immunity Mediated by B Cells, T Cells, and Macrophages. Macrophages and T cells assist B cell-modulated humoral immunity. After the antigens directly bind to MHC class II molecules on the B cells, the membrane-bound antibodies are presented on the B cell surface, setting the markers for macrophages to recognize and further stimulate B cell proliferation [126]. Meanwhile, receptors on the T cells recognize these presented antigens and promote B cell activation [127]. Next, a part of B cells differentiates into plasma cells and expresses antibodies via rough ER while a small proportion of them turns into memory B cells, ensuring secondary immune response. In normal circumstances, all the immune cells keep the balance and the immune microenvironment is in a stable state.

4.3. Immune Evasion and Cytokine Storm in Severe Asthma. If macrophages miss recognizing antigens, this might cause immune evasion [128]. On the contrary, we assume that asthma exacerbation might be associated with the cytokine storm like other infectious diseases [129]. First, antigens promote IFN-γ to activate macrophages and then produce TNF-α, IL-12, and PGE2, constituting a positive feedback loop [130]. Referring to another positive feedback loop, NLRP3 inflammasome is switched on to generate IL-1β and IL-18, recruiting neutrophils to the inflammatory site [131]. Kim et al. [132] described that the elevation of IL-1β and IL-18 via NLRP3 inflammasome led to corticosteroid-resistant asthma and is possibly involved with IL-6 [133]. Meanwhile, in the adaptive immune response, Th1 cells release IL-12 and IFN-γ. They stimulate Th1 cell differentiation and macrophage activation, forming another positive feedback loop to amplify defense ability [134]. Once antigens are controlled, the response is correspondingly weakened by the transmitted signals, forming a negative feedback loop. IL-10 and TGF-β also have the immunosuppressive effect, forming another negative feedback loop [135]. Nevertheless, if the positive feedback loops far exceed the negative feedback loops or the negative ones are too weak to maintain the balance, the immune system will release a mass of cytokines with the wrong signals, causing asthma to worsen [136, 137].

4.4. Role of Extracellular Vesicles in the Crosstalk between T Cells and Macrophages. Extracellular vesicles (EVs), divided into exosomes, microvesicles, and apoptotic bodies, can directly shuttle back and forth freely between the cells, which have the potential to be the mediators of crosstalk between the immune cells [138, 139]. Through EVs, the immune cells interact with each other in an autocrine, paracrine, or remote regulatory manner in asthma progression [140, 141]. It was proved that exosomes carried the nucleic acids (mRNAs and miRNAs) to achieve material delivery [142, 143]. Their characteristics enable them to be accessible to drug delivery in asthma [144]. Hence, we focus on the functions of EVs
in the regulation of T cells and macrophages in asthma pathogenesis.

Some researchers have explored the relationship between EVs and macrophages in asthma pathogenesis. EVs in the lung are primarily derived from epithelial cells and macrophages [145], which can be detected in the sputum and BALF of asthmatic patients [146]. Mohan et al. [147] discovered that exosomal miRNAs (miRNA-let-7a, miRNA-21, miRNA-658, miRNA-24, miRNA-26a, miRNA-99a, miRNA-200c, and miRNA-1268) lay a great di

Table 1: Cytokines participating in the crosstalk between T cells and macrophages.

| Cytokines | Derivation | Interactions between T cells and macrophages | References |
|-----------|------------|---------------------------------------------|------------|
| IL-1β     | Macrophages | Promote CD4⁺T cells, differentiate, and recruit Th2 cells | [101]       |
| IL-2      | Th1 cells   | Enhance macrophage bactericidal capacity      | [116]       |
| IL-4      | Th2 cells   | Motivate macrophage endocytosis function     | [118]       |
| IL-10     | Treg cells, macrophages | Reduce Th2 and Th17 cells, suppress macrophage proliferation | [110, 125] |
| IL-12     | Macrophages | Enhance type 1 inflammation                   | [99]        |
| IL-13     | Th2 cells   | Enhance M2 macrophages                       | [119]       |
| IL-17     | Th17 cells, macrophages | Mediate neutrophilic inflammation and increase macrophages | [108, 122] |
| IL-18     | Macrophages | Drive type 2 inflammation and Th2 cell differentiation | [103]       |
| IL-27     | Macrophages | Suppress Th2-type inflammation               | [113]       |
| IL-33     | Macrophages | Drive Th2-type inflammation                  | [104]       |
| MIF       | Macrophages | Activate CD4⁺T cells and Th2-associated cytokines | [96]        |
| GM-CSF    | Th cells    | Initiate macrophage activation and secretion  | [115]       |
| TNF-α     | Th1 cells, macrophages | Enhance macrophage activation and recruitment, alleviate Th1 and Th2-associated cytokines, IgE and airway remodeling | [107, 116, 117] |
| IFN-γ     | Th1 cells   | Enhance macrophage endocytosis function       | [116]       |
| TGF-β     | Treg cells, macrophages | Suppress macrophages and develop Treg cell proliferation | [112, 125] |
| TSLP      | Macrophages | Stimulate Th2 cell differentiation            | [102]       |
| Prostaglandin | Macrophages | Act on T cells in a paracrine manner          | [97]        |
| LTC⁴      | Macrophages | Modulate Th2 cells and Th2-type inflammation  | [105]       |
| CXCR3L    | Macrophages | Gather Th1 cells                             | [98]        |
| MMP-2     | Macrophages | Downregulate Th2-type inflammation           | [106]       |
| Tim       | T cells     | Regulate macrophage vitality                 | [114]       |
| PPARγ     | Th2 cells   | Increase M2 macrophages and AMs              | [120]       |

References

[1] [101] [110, 125] [99] [119] [108, 122] [103] [113] [104] [96] [115] [107, 116, 117] [116] [112, 125] [102] [97] [105] [98] [106] [114] [120]
exosomes isolated from the exhaled breath condensate of asthmatic patients that increased Th2 cells and diminished Th1 cells [157]. Also, a higher expression of exosomal miRNA-155 in mild asthmatic patients seems to break the equilibrium of Th1/Th2 [158, 159]. However, it was argued that miRNA-155 in exosomes had the anti-inflammatory function that suppressed IL-13 and IL-4 to attenuate type 2 inflammation [160]. On the anti-inflammatory side, Kumar et al. [161] indicated that miRNA-let-7 repressed IL-13 and inhibited type 2 inflammation. Chiou et al. [162] demonstrated that after T cell activation, the EVs isolated from T cells contained tRNA fragments (tRFs), probably removing immune activation. Notably, the mesenchymal stem cell (MSC) generates exosomal miRNA-1470, which remains important in CD4⁺CD25⁺Foxp3⁺ Treg differentiation [163]. Du et al. [164] proved that exosomes released from the MSC increased IL-10 and TGF-β1, thus helping asthmatic patients restore Treg cell proliferation and immunosuppressive functions. Collectively, the above findings emphasize the potential of EVs to mediate immune cell crosstalk in asthma.

5. Conclusion

The imbalance of the immune microenvironment is the main cause of asthma pathogenesis, in which T cells and macrophages engage in from the preliminary stage to the final curtain. The role of T cells, macrophages, and their crosstalk is of great importance in asthma. EVs show great potential as the mediators of this crosstalk. We have proposed a theoretical basis on the hypothesis of the connection between the cytokine storm and the severe asthma; further effort is required to explore this aspect. Based on the current treatment of asthma from corticosteroid to antibody therapy, figuring out the role and the crosstalk between these two cells contribute to developing the novel treatments of asthma. Targets on the T cell-associated and macrophage-associated cytokines or chemokines or miRNAs are critical to attenuating asthma and achieving personalized therapy.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there is no potential conflict of interest associated with this manuscript.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81774074 and 81704154), Shanghai Science and Technology Commission (grant nos. 17401930300 and 18401971300), and Young Elite Scientists Sponsorship Program by China Association for Science and Technology (grant no. 2018QNRC001).

References

[1] A. Papi, C. Brightling, S. E. Pedersen, and H. K. Reddel, “Asthma,” The Lancet, vol. 391, no. 10122, pp. 783–800, 2018.
[2] C. M. Lloyd and S. Saglani, “T cells in asthma: influences of genetics, environment, and T-cell plasticity,” The Journal of Allergy and Clinical Immunology, vol. 131, no. 5, pp. 1267–1274, 2013.
[3] T. Vos, A. D. Flaxman, M. Naghavi et al., “Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010,” The Lancet, vol. 380, no. 9839, pp. 2163–2196, 2012.
[4] P. J. Barnes, “Immunology of asthma and chronic obstructive pulmonary disease,” Nature Reviews Immunology, vol. 8, no. 3, pp. 183–192, 2008.
[5] B. N. Lambrecht, H. Hammad, and J. V. Fahy, “The cytokines of asthma,” Immunity, vol. 50, no. 4, pp. 975–991, 2019.
[6] T. Boonpiyathad, Z. C. Söذur, P. Saitisaksanoa, and C. A. Akdis, “Immunologic mechanisms in asthma,” Seminars in Immunology, vol. 46, p. 101333, 2019.
[7] B. D. Medoff, S. Y. Thomas, and A. D. Luster, “T cell trafficking in allergic asthma: the ins and outs,” Annual Review of Immunology, vol. 26, no. 1, pp. 205–232, 2008.
[8] A. Miadonna, A. Tedeschi, C. Brasca, G. Folco, A. Sala, and R. C. Murphy, “Mediator release after endobronchial antigen challenge in patients with respiratory allergy,” The Journal of Allergy and Clinical Immunology, vol. 85, no. 5, pp. 906–913, 1990.
[9] J. Säffholm, M. L. Mansson, J. Bood et al., “Prostaglandin E2 inhibits mast cell-dependent bronchocstriction in human small airways through the E prostanoid subtype 2 receptor,” The Journal of Allergy and Clinical Immunology, vol. 136, no. 5, pp. 1232–1239.e1, 2015.
[10] R. Ayakanu, N. A. Abdullah, A. K. Radhakrishnan, V. Lechimi Raj, and C. K. Lim, “Relationship between various cytokines implicated in asthma,” Human Immunology, vol. 80, no. 9, pp. 755–763, 2019.
[11] S. J. Barton, S. Ngo, P. Costello et al., “DNA methylation of Th2 lineage determination genes at birth is associated with allergic outcomes in childhood,” Clinical and experimental allergy, journal of the British Society for Allergy and Clinical Immunology, vol. 47, no. 12, pp. 1599–1608, 2017.
[12] S. J. Szabo, B. M. Sullivan, S. L. Peng, and L. H. Glimcher, “MOLECULARMECHANISMSREGULATINGTH1 IMMUNERESPONSES," Annual Review of Immunology, vol. 21, no. 1, pp. 713–758, 2003.
[13] M. Raundhal, C. Morse, A. Khare et al., “High IFN-γ and low SLPI mark severe asthma in mice and humans,” Journal of Clinical Investigation, vol. 125, no. 8, pp. 3037–3050, 2015.
[14] M. Gauthier, K. Chakraborty, T. B. Oriss et al., “Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias,” JCI Insight, vol. 2, no. 13, p. e94580, 2017.
[15] W. Wang, Y. Li, Z. Lv et al., “Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL-33, TSLP, and IL-25) response in the airways epithelium and submucosa,” The Journal of Immunology, vol. 201, no. 8, pp. 2221–2231, 2018.
[16] C. A. Akdis, P. D. Arkwright, M.-C. Brüggen et al., “Type 2 immunity in the skin and lungs,” Allergy, vol. 75, no. 7, pp. 1582–1605, 2020.
[17] P. S. Foster, S. Malby, H. F. Rosenberg et al., “Modeling TH2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma,” Immunological Reviews, vol. 278, no. 1, pp. 20–40, 2017.
[18] J. V. Fahy, “Type 2 inflammation in asthma—present in most, absent in many,” Nature Reviews Immunology, vol. 15, no. 1, pp. 57–65, 2015.
[19] D. A. Kuperman, X. Huang, L. L. Koth et al., “Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma,” Nature Medicine, vol. 8, no. 8, pp. 885–889, 2002.
[20] N. A. Gandhi, B. L. Bennett, N. M. H. Graham, G. Pirozzi, N. Stahl, and G. D. Yancopoulos, “Targeting key proximal drivers of type 2 inflammation in disease,” Nature Reviews Drug Discovery, vol. 15, no. 1, pp. 35–50, 2016.
[21] A. J. Morgan, F. A. Symon, M. A. Berry, I. D. Pavord, C. J. Corrigan, and A. J. Wardlaw, “IL-4—expressing bronchoalveolar T cells from asthmatic and healthy subjects preferentially express CCR3 and CCR4,” The Journal of Allergy and Clinical Immunology, vol. 116, no. 3, pp. 594–600, 2005.
[22] G. Garcia, V. Godot, and M. Humbert, “New chemokine targets for asthma therapy,” Current Allergy and Asthma Reports, vol. 5, no. 2, pp. 155–160, 2005.
[23] H. Hirata, T. Yukawa, A. Tanaka et al., “Th2 cell differentiation from naiveCD4+ T cells is enhanced by autocrine CC chemokines in atopic diseases,” Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology, vol. 49, no. 4, pp. 474–483, 2019.
[24] C. A. Herrick and K. Bottomly, “To respond or not to respond: T cells in allergic asthma,” Nature Reviews Immunology, vol. 3, no. 5, pp. 405–412, 2003.
[25] M. C. Peters and S. E. Wenzel, “Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma,” The Lancet, vol. 395, no. 10221, pp. 371–383, 2020.
[26] D. J. Tumes, M. Papadopoulos, Y. Endo, A. Onodera, K. Hirahara, and T. Nakayama, “Epigenetic regulation of T-helper cell differentiation, memory, and plasticity in allergic asthma,” Immunological Reviews, vol. 278, no. 1, pp. 8–19, 2017.
[27] J. F. Alcorn, C. R. Crowe, and J. K. Kolls, “TH17 cells in asthma and COPD,” Annual Review of Physiology, vol. 72, no. 1, pp. 495–516, 2010.
[28] S. Schnyder-Candrian, D. Togbe, I. Couillin et al., “Interleukin-17 is a negative regulator of established allergic asthma,” The Journal of Experimental Medicine, vol. 203, no. 12, pp. 2715–2725, 2006.
[29] J. Chesné, F. Braza, G. Mahay, S. Brouard, M. Aronica, and A. Magnan, “IL-17 in Severe Asthma. Where Do We Stand?,” American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 10, pp. 1094–1101, 2014.
[30] M. S. Rahman, A. Yamasaki, J. Yang, L. Shan, A. J. Halayko, and A. S. Gounni, “IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK, and p38) pathways,” The Journal of Immunology, vol. 177, no. 6, pp. 4064–4071, 2006.
[31] J. Louten, K. Boniface, and R. de Waal Malefyt, “Development and function of TH17 cells in health and disease,” Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1004–1011, 2009.
[32] D. H. Strickland and P. G. Holt, “T regulatory cells in childhood asthma,” Trends in Immunology, vol. 32, no. 9, pp. 420–427, 2011.
[33] R. Afshar, J. P. Strassner, E. Seung et al., “Compartmentalized chemokine-dependent regulatory T-cell inhibition of allergic pulmonary inflammation,” The Journal of Allergy and Clinical Immunology, vol. 131, no. 6, pp. 1644–1652.e4, 2013.
[34] L. W. Collison, V. Chaturvedi, A. L. Henderson et al., “IL-35-mediated induction of a potent regulatory T cell population,” Nature Immunology, vol. 11, no. 12, pp. 1093–1101, 2010.
[35] R. H. Wilson, G. S. Whitehead, H. Nakano, M. E. Free, J. K. Kolls, and D. N. Cook, “Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 8, pp. 720–730, 2009.
[36] D. F. Choy, K. M. Hart, L. A. Borthwick et al., “TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma,” Science Translational Medicine, vol. 7, no. 301, p. 301ra129, 2015.
[37] P. J. Barnes, “Targeting cytokines to treat asthma and chronic obstructive pulmonary disease,” Nature Reviews Immunology, vol. 18, no. 7, pp. 454–466, 2018.
[38] M. Akdis, O. Palomares, W. van de Veen, M. van Splunter, and C. A. Akdis, “TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection,” The Journal of Allergy and Clinical Immunology, vol. 129, no. 6, pp. 1438–1449, 2012.
[39] A. G. Besnard, R. Sabat, L. Dumoutier et al., “Dual role of IL-22 in allergic airway inflammation and its crosstalk with IL-17A,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 9, pp. 1153–1163, 2011.
[40] K. Nakagome, M. Imamura, K. Kawahata et al., “High expression of IL-22 suppresses antigen-induced immune responses and eosinophilic airway inflammation via an IL-10-associated mechanism,” The Journal of Immunology, vol. 187, no. 10, pp. 5077–5089, 2011.
[41] T. Duhen, R. Geiger, D. Jarrossay, A. Lanzavecchia, and W. Collison, V. Chaturvedi, A. L. Henderson et al., “IL-35-mediated induction of a potent regulatory T cell population,” Nature Immunology, vol. 11, no. 12, pp. 1093–1101, 2010.
[42] H. C. Chang, S. Sehra, R. Goswami et al., “The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation,” Nature Immunology, vol. 11, no. 6, pp. 527–534, 2010.
[43] V. Staudt, E. Bothur, M. Klein et al., “Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells,” Immunity, vol. 33, no. 2, pp. 192–202, 2010.
[44] L. Benevides, R. S. Costa, L. A. Tavares et al., “B lymphocyte-induced maturation protein 1 controls TH9 cell development, IL-9 production, and allergic inflammation,” The Journal of Allergy and Clinical Immunology, vol. 143, no. 3, pp. 1119–1130.e3, 2019.
Mediators of Inflammation

[46] C. P. Jones, L. G. Gregory, B. Causton, G. A. Campbell, and C. M. Lloyd, “Activin A and TGF-β promote TH9 cell–mediated pulmonary allergic pathology,” Journal of Allergy and Clinical Immunology, vol. 129, no. 4, pp. 1000–1010.e3, 2012.

[47] M. A. M. Saeki, O. Kaminuma, T. Nishimura, N. Kitamura, A. Mori, and T. Hiroi, “TH9 cells induce steroid-resistant bronchial hyperresponsiveness in mice,” Allergology International, vol. 66S, pp. S35–S40, 2017.

[48] S. Swaidani, K. Bulek, Z. Kang et al., “T cell-derived Act1 is necessary for IL-25–mediated Th2 responses and allergic airway inflammation,” The Journal of Immunology, vol. 187, no. 6, pp. 3155–3164, 2011.

[49] D. M. Moldaver, M. Larche, and C. D. Rudulier, “An update on lymphocyte subtypes in asthma and airway disease,” Chest, vol. 151, no. 5, pp. 1122–1130, 2017.

[50] G. Varricchi, J. Harker, F. Borriello, G. Marone, S. R. Durham, and M. H. Shamsi, “T follicular helper (Tfh) cells in normal immune responses and in allergic disorders,” Allergy, vol. 71, no. 8, pp. 1086–1094, 2016.

[51] M. Dell’Arlinga and R. L. Reinhardt, “Notch signaling represents an important checkpoint between follicular T-helper and canonical T-helper 2 cell fate,” Mucosal Immunology, vol. 11, no. 4, pp. 1079–1091, 2018.

[52] A. Ballesteros-Tato, T. D. Randall, F. E. Lund, R. Spolski, W. J. Leonard, and B. León, “T follicular helper cell plasticity shapes pathogenic T helper 2 cell-mediated immunity to inhaled dust mite,” Immunity, vol. 44, no. 2, pp. 259–273, 2016.

[53] L. Chávez-Galán, M. C. Arenas-del Angel, E. Zenteno, R. Chávez, and R. Lascurain, “Cell Death Mechanisms Induced by Cytotoxic Lymphocytes,” Cellular & Molecular Immunology, vol. 6, no. 1, pp. 15–25, 2009.

[54] P. P. Banti, S. Timalsena, A. Wongkajornsip, and K. Soontrapa, “Cytokine-induced killer cells: a novel treatment for allergic airway inflammation,” PLoS One, vol. 12, no. 10, p. e0186971, 2017.

[55] J. R. Victor, G. Lezmi, and M. Leite-de-Moraes, “New insights into asthma inflammation: focus on iNKT, MAIT, and γδT cells,” Clinical Reviews in Allergy & Immunology, 2020.

[56] S. P. Berzins and D. S. Ritchie, “Natural killer T cells: drivers or passengers in preventing human disease?,” Nature Reviews Immunology, vol. 14, no. 9, pp. 640–646, 2014.

[57] O. Akbari, P. Stock, E. Meyer et al., “Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity,” Nature Medicine, vol. 9, no. 5, pp. 582–588, 2003.

[58] G. Lezmi and M. Leite-de-Moraes, “Invariant natural killer T and mucosal-associated invariant T cells in asthmatic patients,” Frontiers in Immunology, vol. 9, p. 1766, 2018.

[59] S. Crotty, R. J. Johnston, and S. P. Schoenberger, “Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation,” Nature Immunology, vol. 11, no. 2, pp. 114–120, 2010.

[60] G. Seumois, L. Chávez, A. Gerasimova et al., “Epigenomic analysis of primary human T cells reveals enhancers associated with TH2 memory cell differentiation and asthma susceptibility,” Nature Immunology, vol. 15, no. 8, pp. 777–788, 2014.

[61] K. Nakagome, M. Dohi, K. Okunishi et al., “Antigen-sensitized CD4+CD62Llow memory effector T helper 2 cells can induce airway hyperresponsiveness in an antigen free setting,” Respiratory Research, vol. 6, no. 1, 2005.

[62] B. D. Honadowicz, D. An, J. M. Schenk et al., “Interleukin-2-dependent allergen-specific tissue-resident memory cells drive asthma,” Immunity, vol. 44, no. 1, pp. 155–166, 2016.

[63] Y. Endo, K. Hirahara, T. Iinuma et al., “The interleukin-33–p38 kinase axis confers memory T helper 2 cell pathogenicity in the airway,” Immunity, vol. 42, no. 2, pp. 294–308, 2015.

[64] C. H. Huang, X.-L. Loo, I.-C. Kuo et al., “Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35,” The Journal of Immunology, vol. 187, no. 1, pp. 462–471, 2011.

[65] M. J. Leckie, G. R. Jenkins, J. Khan et al., “Spumum T lymphocytes in asthma, COPD and healthy subjects have the phenotype of activated intraepithelial T cells (CD69+ CD103+),” Thorax, vol. 58, no. 1, pp. 23–29, 2003.

[66] S. Sharma, X. Zhou, D. M. Athibault et al., “A genome-wide survey of CD4(+) lymphocyte regulatory genetic variants identifies novel asthma genes,” The Journal of Allergy and Clinical Immunology, vol. 134, no. 5, pp. 1153–1162, 2014.

[67] E. Sajti, V. M. Link, Z. Ouyang et al., “Transcriptomic and epigenetic mechanisms underlying myeloid diversity in the lung,” Nature Immunology, vol. 21, no. 2, pp. 221–231, 2020.

[68] P. J. Murray and T. A. Wynn, “Protective and pathogenic functions of macrophage subsets,” Nature Reviews Immunology, vol. 11, no. 11, pp. 723–737, 2011.

[69] Y. G. Lee, J. J. Jeong, S. N. Niihuis et al., “ Recruited Alveolar Macrophages, in Response to Airway Epithelial-Derived Monocyte Chemoattractant Protein 1 (CCL2), Regulate Airway Inflammation and Remodeling in Allergic Asthma,” American Journal of Respiratory Cell and Molecular Biology, vol. 52, no. 6, pp. 772–784, 2015.

[70] E. Careau and E. Y. Bissonnette, “Adaptive Transfer of Alveolar Macrophages Abrogates Bronchial Hyperresponsive- ness,” American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 1, pp. 22–27, 2004.

[71] P. J. Murray, J. E. Allen, S. K. Biswas et al., “Macrophage activation and polarization: nomenclature and experimental guidelines,” Immunity, vol. 41, no. 1, pp. 14–20, 2014.

[72] P. J. Murray, “ Macrophage polarization,” Annual Review of Physiology, vol. 79, no. 1, pp. 541–566, 2017.

[73] A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, “The chemokine system in diverse forms of macrophage activation and polarization,” Trends in Immunology, vol. 25, no. 12, pp. 677–686, 2004.

[74] S. Gordon, “Alternative activation of macrophages,” Nature Reviews Immunology, vol. 3, no. 1, pp. 23–35, 2003.

[75] M. C. Bosco, “Macrophage polarization: reaching across the aisle?,” The Journal of Allergy and Clinical Immunology, vol. 143, no. 4, pp. 1348–1350, 2019.

[76] M. R. Karta, M. L. Gavala, C. S. Curran et al., “LPS Modulates Rhinovirus-Induced Chemokine Secretion in Monocytes and Macrophages,” American Journal of Respiratory Cell and Molecular Biology, vol. 51, no. 1, pp. 125–134, 2014.
[78] E. Goleva, P. J. Hauk, C. F. Hall et al., "Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages," *Journal of Allergy and Clinical Immunology*, vol. 122, no. 3, pp. 550–559.e3, 2008.

[79] P.-O. Girodet, D. Nguyen, J. D. Mancini et al., "Alternative Macrophage Activation Is Increased in Asthma," *American Journal of Respiratory Cell and Molecular Biology*, vol. 55, no. 4, pp. 467–475, 2016.

[80] M. H. Abdelaziz, S. F. Abdelwahab, J. Wan et al., "Alternatively activated macrophages; a double-edged sword in allergic asthma," *Journal of translational medicine*, vol. 18, no. 1, p. 58, 2020.

[81] B. N. Melgert, N. H. ten Hacken, B. Rutgers, W. Timens, D. S. Postma, and M. N. Hylkema, "More alternative activation of macrophages in lungs of asthmatic patients," *The Journal of Allergy and Clinical Immunology*, vol. 127, no. 3, pp. 831–833, 2011.

[82] B. N. Melgert, T. B. Oriss, Z. Qi et al., "Macrophages," *American Journal of Respiratory Cell and Molecular Biology*, vol. 42, no. 5, pp. 595–603, 2010.

[83] Y. Liu, X. Gao, Y. Miao et al., "NLRP3 regulates macrophage M2 polarization through up-regulation of IL-4 in asthma," *The Biochemical Journal*, vol. 475, no. 12, pp. 1995–2008, 2018.

[84] A. Shapouri-Moghaddam, S. Mohammadian, H. Vazini et al., "Macrophage plasticity, polarization, and function in health and disease," *Journal of Cellular Physiology*, vol. 233, no. 9, pp. 6425–6440, 2018.

[85] D. Thiriou, I. Morianos, G. Xanthou, and K. Samitas, "Innate immunity as the orchestrator of allergic airway inflammation and resolution in asthma," *International Immunopharmacology*, vol. 48, pp. 43–54, 2017.

[86] F. Puttur, L. G. Gregory, and C. M. Lloyd, "Airway macrophages as the guardians of tissue repair in the lung," *Immunology & Cell Biology*, vol. 97, no. 3, pp. 246–257, 2019.

[87] K. Jandl, E. Stacher, Z. Bálint et al., "Activated prostaglandin D2 receptors on macrophages enhance neutrophil recruitment into the lung," *The Journal of Allergy and Clinical Immunology*, vol. 137, no. 3, pp. 833–843, 2016.

[88] J. P. Choi, S. Y. Park, K. A. Moon et al., "Macrophage-derived progranulin promotes allergen-induced airway inflammation," *Allergy*, vol. 75, no. 5, pp. 1133–1145, 2020.

[89] Y. Wang, J. Zhu, L. Zhang et al., "Role of C/EBP homologous protein and endoplasmic reticulum stress in asthma exacerbation by regulating the IL-4/signal transducer and activator of transcription 6/transcription factor EC/IL-4 receptor a positive feedback loop in M2 macrophages," *The Journal of Allergy and Clinical Immunology*, vol. 140, no. 6, pp. 1550–1561.e8, 2017.

[90] E. R. Unanue, "Antigen-presenting function of the macrophage," *Annual Review of Immunology*, vol. 2, no. 1, pp. 395–428, 1984.

[91] R. Pawankar, M. Hayashi, S. Yamanishi, and T. Igarashi, "The paradigm of cytokine networks in allergic airway inflammation," *Current Opinion in Allergy and Clinical Immunology*, vol. 15, no. 1, pp. 41–48, 2015.

[92] N. Hizawa, E. Yamaguchi, D. Takahashi, J. Nishihira, and M. Nishimura, "Functional Polymorphisms in the Promoter Region of Macrophage Migration Inhibitory Factor and Atopy," *American Journal of Respiratory and Critical Care Medicine*, vol. 169, no. 9, pp. 1014–1018, 2004.

[93] K. C. Beier, T. Kallinich, and E. Hamelmann, "T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease," *European Respiratory Journal*, vol. 30, no. 2, pp. 383–390, 2007.

[94] K. C. Beier, T. Kallinich, and E. Hamelmann, "Master switches of T-cell activation and differentiation," *European Respiratory Journal*, vol. 29, no. 4, pp. 804–812, 2007.

[95] R. L. Blumenthal, D. E. Campbell, P. Hwang, R. H. DeKruyff, L. R. Frankel, and D. T. Umetsu, "Human alveolar macrophages induce functional inactivation in antigen-specific CD4 T cells," *The Journal of Allergy and Clinical Immunology*, vol. 107, no. 2, pp. 258–264, 2001.

[96] M. T. Bozza, L. Lintomen, J. Z. Kitoko, C. N. Paiva, and P. C. Olsen, "The role of MIF on eosinophil biology and eosinophilic inflammation," *Clinical Reviews in Allergy & Immunology*, vol. 58, no. 1, pp. 15–24, 2020.

[97] A. Lukic, P. Larssen, A. Fauland et al., "GM-CSF– and M-CSF–primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures," *The FASEB Journal*, vol. 31, no. 10, pp. 4370–4381, 2017.

[98] W. J. Branchett, H. Stölting, R. A. Oliver et al., "A T cell myeloid IL-10 axis regulates pathogenic IFN-γ-dependent immunity in a mouse model of type 2-low asthma," *The Journal of Allergy and Clinical Immunology*, vol. 145, no. 2, pp. 666–678.e9, 2020.

[99] P. Poulou, A. Spahr, E. Careau, V. Turmel, and E. Y. Bissonnette, "Alveolar macrophages from allergic lungs are not committed to a pro-allergic response and can reduce airway hyperresponsiveness following ex vivo culture," *Clinical and Experimental Allergy*, vol. 38, no. 3, pp. 529–538, 2008.

[100] T. A. Wynn and K. M. Vannella, "Macrophages in tissue repair, regeneration, and fibrosis," *Immunology*, vol. 44, no. 3, pp. 450–462, 2016.

[101] C. Herbert, M. M. Scott, K. H. Scruton et al., "Alveolar macrophages stimulate enhanced cytokine production by pulmonary CD4+ T-lymphocytes in an exacerbation of murine chronic asthma," *American Journal of Pathology*, vol. 177, no. 4, pp. 1657–1664, 2010.

[102] J.-F. Lai, L. J. Thompson, and S. F. Ziegler, "TSLP drives acute TH2-cell differentiation in lungs," *The Journal of Allergy and Clinical Immunology*, vol. 138, no. 4, pp. 670–678.e9, 2006.

[103] M. Sawada, T. Kawayama, H. Imaoka et al., "IL-18 induces airway hyperresponsiveness and pulmonary inflammation via CD4+ T cell and IL-13," *PLoS One*, vol. 8, no. 1, p. e54623, 2013.

[104] M. Wells-Karp, R. Rani, K. Dienger et al., "Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection," *The Journal of Experimental Medicine*, vol. 209, no. 3, pp. 607–622, 2012.

[105] T. M. Laidlaw and J. A. Boyce, "Cysteinyl leukotriene receptors, old and new; implications for asthma," *Clinical & Experimental Allergy*, vol. 42, no. 9, pp. 1313–1320, 2012.

[106] Y. Takahashi, T. Kobayashi, C. N. D’Alessandro-Gabazza et al., "Protective role of matrix metalloproteinase-2 in allergic bronchial asthma," *Frontiers in Immunology*, vol. 10, p. 1795, 2019.

[107] J. Y. Kim, J. H. Sohn, J. M. Choi et al., "Alveolar macrophages play a key role in cockroach-induced allergic inflammation via TNF-α pathway," *PLoS One*, vol. 7, no. 10, p. e47971, 2012.
Mediators of Inflammation

[108] C. Song, L. Luo, Z. Lei et al., "IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma," The Journal of Immunology, vol. 181, no. 9, pp. 6117–6124, 2008.

[109] M. Crapper-Pregont, J. Yeo, R. L. Sanchez, and D. A. Kuperman, "Dendritic cells and alveolar macrophages mediate IL-13-induced airway inflammation and chemokine production," The Journal of Allergy and Clinical Immunology, vol. 129, no. 6, pp. 1621–1627.e3, 2012.

[110] H. Kawano, H. Kayama, T. Nakama, T. Hashimoto, E. Umemoto, and K. Takeda, "IL-10-producing lung interstitial macrophages prevent neutrophilic asthma," International Immunology, vol. 28, no. 10, pp. 489–501, 2016.

[111] S. Chakarov, H. Y. Lim, L. Tan et al., "Two distinct interstitial macrophage populations coexist across tissues in specific submucosal niches," Science, vol. 363, no. 6432, p. eaau0964, 2019.

[112] P. Sorooosh, T. A. Doherty, W. Duan et al., "Lung-resident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance," The Journal of Experimental Medicine, vol. 210, no. 4, pp. 775–788, 2013.

[113] D. Lu, J. Lu, X. Ji et al., "IL-27 suppresses airway inflammation, hyperresponsiveness and remodeling via the STAT1 and STAT3 pathways in mice with allergic asthma," International Journal of Molecular Sciences, vol. 46, no. 2, pp. 641–652, 2020.

[114] V. K. Kuchroo, D. T. Uematsu, R. H. DeKruyff, and G. J. Freeman, "The TIM gene family: emerging roles in immunity and disease," Nature Reviews Immunology, vol. 3, no. 6, pp. 454–462, 2003.

[115] S. Bashir, Y. Sharma, A. Elahi, and F. Khan, "Macrophage polarization: the link between inflammation and related diseases," Inflammation Research, vol. 65, no. 1, pp. 1–11, 2016.

[116] Q. Ma, "Polarization of immune cells in the pathologic response to inhaled particulates," Frontiers in Immunology, vol. 11, 2020.

[117] S. Mukhopadhyay, P. Malik, S. K. Arora, and T. K. Mukherjee, "Intercellular adhesion molecule-1 as a drug target in asthma and rhinitis," Respiratory, vol. 19, no. 4, pp. 508–513, 2014.

[118] S. Romagnani, "T-cell subsets (Th1 versus Th2)," Annals of Allergy, Asthma & Immunology, vol. 85, no. 1, pp. 9–21, 2000.

[119] R. Edukulla, B. Singh, A. G. Jegga, V. Sontake, S. R. Dillon, and S. K. Madala, "Th2 cytokines augment IL-31/IL-31RA interactions via STAT6-dependent IL-31RA expression," The Journal of Biological Chemistry, vol. 290, no. 21, pp. 13510–13520, 2015.

[120] S. P. Nobs, S. Natali, L. Pohlmeier et al., "PPARy in dendritic cells and T cells drives pathogenic type-2 effector responses in lung inflammation," The Journal of Experimental Medicine, vol. 214, no. 10, pp. 3015–3035, 2017.

[121] E. R. Banerjee and W. R. Henderson Jr., "Role of T cells in a gp91phox knockout murine model of acute allergic asthma," Allergy, Asthma & Clinical Immunology, vol. 9, no. 1, 2013.

[122] N. Mizutani, T. Nabe, and S. Yoshino, "IL-17A promotes the exacerbation of IL-33-induced airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling in mice," The Journal of Immunology, vol. 192, no. 4, pp. 1372–1384, 2014.

[123] E. Y. Kim, J. T. Battaile, A. C. Patel et al., "Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease," Nature Medicine, vol. 14, no. 6, pp. 633–640, 2008.

[124] H. Y. Kim, Y. J. Chang, S. Subramanian et al., "Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity," The Journal of Allergy and Clinical Immunology, vol. 129, no. 1, pp. 216–227.e6, 2012.

[125] F. Chung, "Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma," Mediators of Inflammation, vol. 10, no. 2, pp. 51–59, 2001.

[126] J. H. Lam, F. L. Smith, and N. Baumgarth, "B cell activation and response regulation during viral infections," Viral Immunology, vol. 33, no. 4, pp. 294–306, 2020.

[127] A. Biram and Z. Shulman, "T cell help to B cells: cognate and atypical interactions in peripheral and intestinal lymphoid tissues," Immunological Reviews, vol. 296, no. 1, pp. 36–47, 2020.

[128] A. M. Fitzpatrick, F. Holguin, W. G. Teague, and L. A. S. Brown, "Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma," The Journal of Allergy and Clinical Immunology, vol. 121, no. 6, pp. 1372–1378.e3, 2008.

[129] E. M. Behrens and G. A. Koretzky, "Review: cytokine storm syndrome: looking toward the precision medicine era," Arthritis & Rheumatology, vol. 69, no. 6, pp. 1135–1143, 2017.

[130] M. R. Jenkins, J. A. Rudder-Schmidt, J. A. Lopez et al., "Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time," The Journal of Experimental Medicine, vol. 212, no. 3, pp. 307–317, 2015.

[131] I. Tillie-Leblond, P. Gosset, and A. B. Tonnel, "Inflammatory events in severe acute asthma," Allergy, vol. 60, no. 1, pp. 23–29, 2005.

[132] R. Y. Kim, J. W. Pinkerton, A. T. Essilfe et al., "Role for NLRP3 inflammasome-mediated, IL-1β-dependent responses in severe, steroid-resistant asthma," American Journal of Respiratory and Critical Care Medicine, vol. 196, no. 3, pp. 283–297, 2017.

[133] T. Tanaka, M. Narazaki, and T. Kishimoto, "Immunotherapeutic implications of IL-6 blockade for cytokine storm," Immunotherapy, vol. 8, no. 8, pp. 959–970, 2016.

[134] H. Y. Kim, R. H. Dekruyff, and D. T. Uematsu, "The many paths to asthma: phenotype shaped by innate and adaptive immunity," Nature Immunology, vol. 11, no. 7, pp. 577–584, 2010.

[135] W. J. Branchett and C. M. Lloyd, "Regulatory cytokine function in the respiratory tract," Mucosal Immunology, vol. 12, no. 3, pp. 589–600, 2019.

[136] S. Mahajan, C. E. Decker, Z. Yang, D. Veis, E. D. Mellins, and R. Faccio, "Plcγ2/Tmem178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome," Journal of Autoimmunity, vol. 100, pp. 62–74, 2019.

[137] M. Yang, R. K. Kumar, P. M. Hansbro, and P. S. Foster, "Emerging roles of pulmonary macrophages in driving the development of severe asthma," Journal of Leukocyte Biology, vol. 91, no. 4, pp. 557–569, 2012.

[138] M. Colombo, G. Raposo, and C. Thery, "Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles," Annual Review of Cell and Developmental Biology, vol. 30, no. 1, pp. 255–289, 2014.
Extracellular vesicles can present allergen peptides and activate T cell differentiation, and miR-155, a microRNA involved in the regulation of allergic respiratory diseases, is also a potential target. The potential use of exosomes as therapeutic agents in treating allergic asthma and chronic obstructive pulmonary disease (COPD) is promising. The role of miR-29c/B7-H3 in regulating T cell differentiation and miR-223 in inhibiting T cell proliferation and production of TH2-like cytokines is also highlighted. The potential use of extracellular vesicles as novel communicators in lung diseases, and the impact of microRNAs on alterations of gene regulatory networks in allergic diseases, is discussed. The importance of miRNA-126 in serum exosomes of allergic asthma patients and the role of lncRNA MALAT1/-miR-155/CTLA4 axis in altering Th1/Th2 balance of asthma is also addressed.

Extracellular vesicles, including exosomes, can present allergen peptides and activate T cell differentiation. The role of miR-29c/B7-H3 in regulating T cell differentiation and miR-223 in inhibiting T cell proliferation and production of TH2-like cytokines is also highlighted. The potential use of extracellular vesicles as novel communicators in lung diseases, and the impact of microRNAs on alterations of gene regulatory networks in allergic diseases, is discussed. The importance of miRNA-126 in serum exosomes of allergic asthma patients and the role of lncRNA MALAT1/-miR-155/CTLA4 axis in altering Th1/Th2 balance of asthma is also addressed.